Brian Reed: Hey. Good to be back.
Eliza Ward: Yeah, and we've got — okay, something landed this morning that I think is worth sitting with for a minute.
Brian Reed: Lakefront's half-year results. Right. So that was August 10th, and it's the first time we actually get a public look at how the Ouro Medicines deal is sitting on their books.
Eliza Ward: And the deal itself — Gilead Sciences and Lakefront closed the Ouro acquisition on June 4th. $1.675 billion upfront, split exactly equally. That's the confirmed part.
Brian Reed: The number that stopped me was the €1.6 billion cash forecast. Lakefront says they can fund the whole portfolio through the first gamgertamig approval on that. And I — let me see — I don't know whether to read that as reassuring or as a claim that has no date attached to it.
Eliza Ward: Wait — that's exactly it. "Through first approval" is doing a lot of work in that sentence.
Brian Reed: Right. And they announced a €50 million share repurchase on the same day, which is — that's a confidence signal. Or it's meant to read as one.
Eliza Ward: Meant to read as one. Yeah. And the asset at the center of all this is gamgertamig — OM336, BCMAxCD3 bispecific T-cell engager, autoimmune diseases. That's what they paid $1.675 billion for. Plus up to $500 million in contingent milestones, also split equally.
Brian Reed: But that 50/50 framing — I want to pull on that thread, because the actual structure is not symmetric. Gilead holds exclusive worldwide commercialization rights for gamgertamig. Full stop. Lakefront runs the Phase 1/2 studies.
Eliza Ward: The earliest, highest-attrition stage.
Brian Reed: Right. So before I go further — what actually is gamgertamig doing, mechanically? Because I think the name swallows the idea.
Eliza Ward: It's a matchmaker protein. That's — actually, that's the cleanest way I've got it. One hand grabs the disease-driving cell, the other hand grabs a T cell that's already inside the patient. Forces them together. The T cell destroys the target. No lab-engineered cells, just a protein redirecting what the patient already has.
Brian Reed: Okay. That's — yeah, that's a genuinely different thing from cell therapy.
Eliza Ward: Which matters because Lakefront shut its entire cell therapy unit in October 2025. This isn't a continuation of that — it's a different technology class. The asymmetry is this: Gilead's Q2 filing lists roughly $1.0 billion in acquired IPR&D for Ouro. Their stated share of the upfront was $837.5 million. So the book value is already higher than what they wired.
Brian Reed: And to put that $1.0 billion in proportion — Gilead also completed the Arcellx acquisition in Q2 2026 and recorded $7.0 billion in IPR&D for that one. So Ouro is a meaningful but decidedly smaller concurrent bet.
Eliza Ward: Wait — and Keymed Biosciences holds licensed rights to certain territories for gamgertamig commercialization. On undisclosed terms. So 'exclusive worldwide' for Gilead already has a carve-out we can't price.
Brian Reed: So the word 'equal' in the press release is doing — I mean, it's covering a structure where one partner controls commercialization, the other carries early-stage burn, and a third party holds territorial rights nobody's quantified. That's not 50/50. That's 50/50 on the invoice.
Eliza Ward: And the '50/50 on the invoice' framing — that's actually the cleanest way into what I want to push on, because the same slippage is happening with the first-in-class label.
Brian Reed: The 'potential first-and-best-in-class' claim. Yeah. So — hang on — who's getting that wrong?
Eliza Ward: The take circulating is that gamgertamig basically owns the BCMAxCD3 bispecific space. And it doesn't. AbbVie has etentamig — ABBV-383 — same mechanism, already in Phase 3.
Brian Reed: Right, but etentamig is in Phase 3 for multiple myeloma. Not autoimmune disease. AIHA and immune thrombocytopenia are a genuinely different indication. So is the circle Lakefront's drawing actually tight enough to hold?
Eliza Ward: Maybe. The FDA did grant gamgertamig Fast Track and Orphan Drug Designation for both AIHA and immune thrombocytopenia. Those aren't marketing badges — Fast Track means FDA thinks there's real unmet need, Orphan means the patient population is small enough that standard commercial math doesn't work.
Brian Reed: And that unmet need is real. Someone living with autoimmune hemolytic anemia right now — their immune system is destroying their own red blood cells — there are very few approved options. And gamgertamig is in Phase 1/2. That's realistically years from any access.
Eliza Ward: Wait — and Lakefront's own language says 'potential' first-and-best-in-class. That word is doing real work. It's the honest hedge.
Brian Reed: So the claim is defensible only if you hold the indication boundary — autoimmune, not oncology — and only if no other BCMAxCD3 program moves into that space before gamgertamig completes Phase 1/2. Which, I mean, AbbVie isn't standing still. That boundary could get a lot narrower. And the part that actually ties this to the cash question — whether Lakefront's runway survives that timeline — that's what I want to look at next.
Eliza Ward: Right. First-in-class in autoimmune, as of today. Full stop is the part nobody should be printing.
Brian Reed: Cash that can fund to approval — that's the whole argument. Lakefront closed its cell therapy unit in October 2025 with roughly €3 billion in hand. They didn't build this from a lab. They bought into a pipeline. Gosebruch's entire thesis is: enough cash buys enough science fast enough.
Eliza Ward: And gamgertamig is the clearest test of that thesis. Not a late-stage asset they're shepherding home — Phase 1/2, early attrition risk, timeline unspecified.
Brian Reed: Right — and the €1.6 billion floor only holds if approval comes before the cash does. No named date means that floor is actually... I mean, it's a conditional, not a commitment.
Eliza Ward: Hold on — the €50 million buyback sits right next to that conditional. That's real money out the door. You don't do a repurchase if you think the floor is fragile.
Brian Reed: Or you do it because — wait, actually — the ~€2 billion year-end 2026 guidance is the more grounded number. That one has a date. December 31st. The buyback is consistent with that. The approval runway is the part that's floating.
Eliza Ward: Three more programs. That's the part nobody's talking about. Lakefront in-licensed three additional preclinical autoimmune programs from Ouro — and each one, Gilead only opts in after clinical proof-of-concept. So Lakefront funds early risk three more times before Gilead decides if they want in.
Brian Reed: That's — yeah. Henry Gosebruch is essentially building a development-services structure and calling it a partnership.
Eliza Ward: The thing to watch — and this is actually nameable — is whether Gilead exercises any of those three opt-ins before gamgertamig clears Phase 1/2. If they do, the 50/50 profit-split structure proves it's real. If they don't, Lakefront's spent down the €1.6 billion floor funding options Gilead never took.
Brian Reed: And Gosebruch's acquisition strategy either produces a pipeline or produces a very expensive record of Gilead's right to say no.
Eliza Ward: Which is — I mean, that's where I land. Gilead's Daniel O'Day described this whole Q2 as growth momentum. The Ouro deal, the Arcellx deal. From Gilead's seat, gamgertamig is one line item in a quarter. From Lakefront's seat it's the thesis.
Brian Reed: And that asymmetry — that's the open question I can't close. If gamgertamig works, what does winning actually look like for Lakefront? Gilead holds exclusive worldwide commercialization. Lakefront gets a share of profits on future programs after proof-of-concept. But the primary asset — the one the FDA already gave Fast Track and Orphan Drug Designation — Lakefront doesn't commercialize that. At all.
Eliza Ward: No. And the €1.6 billion runway — that's contingent on an approval date nobody's published. So I genuinely don't know if Lakefront's ceiling is 'meaningful upside' or 'well-funded junior partner.' Those are different companies.
Brian Reed: The thing that would actually settle it for me — and I don't think this exists yet publicly — is any disclosure of an assumed approval timeline inside that €1.6 billion forecast. If Lakefront is modeling a 2028 approval versus 2031, the cash floor means something completely different. Until there's a date attached, that number is... it's a claim, not a commitment.
Eliza Ward: That's the next thing I'm watching for. Any public filing or guidance update where Lakefront actually names a gamgertamig approval timeline. Without it, the €1.6 billion floats. That's where I'm stopping.
